Novel Drug for Menopause Symptoms Passes Phase 3 Test

The novel NK3 receptor-inhibitor fezolinetant controlled vasomotor symptoms of menopause over 52 weeks in the phase 3 SKYLIGHT 2 trial.
Medscape Medical News

source https://www.medscape.com/viewarticle/975711?src=rss